 |
|
Metastatic Non-Oat-Cell Bronchogenic CarcinomaTherapy With Cyclophosphamide, Doxorubicin, Methotrexate, and Procarbazine (CAMP)
Jacob D. Bitran, MD;
Richard K. Desser, MD;
Thomas DeMeester, MD;
Harvey M. Golomb, MD
JAMA. 1978;240(25):2743-2746.
Abstract
Fifty-four patients with metastatic non-oat-cell bronchogenic carcinoma were treated with cyclophosphamide, doxorubicin hydrochloride (Adriamycin), methotrexate, and procarbazine hydrochloride (CAMP). Eighteen of 51 of these patients with measurable disease showed an objective response to CAMP chemotherapy, with a median survival of 12.6 months. Eight of the 18 patients are still alive, and two have been in continuous remission for 20 and 26 months. Survival for patients with stable disease was 12 months, similar to that for patients demonstrating objective regression in response to CAMP treatment. Weight loss, performance status, and dominant site of metastases proved to be important prognostic factors. The CAMP regimen was well tolerated; there were only two drug-related deaths, both secondary to infectious complications.
(JAMA 240:2743-2746, 1978)
Author Affiliations
From the Departments of Medicine (Drs Bitran, Desser and Golomb), Michael Reese Medical Center and the University of Chicago Hospitals and Clinics, Chicago, and the Department of Surgery (Dr DeMeester), the University of Chicago Hospitals and Clinics, the University of Chicago-Pritzker School of Medicine, Chicago.
Footnotes
Reprint requests to Department of Medicine, Section of Hematology-Oncology, Michael Reese Medical Center, 2929 S Ellis, Chicago, IL 60616 (Dr Bitran).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
A Model to Select Regimens for Phase III Trials for Patients with Advanced-Stage Non-Small Cell Lung Cancer
Freidlin et al.
Clin. Cancer Res. 2003;9:917-922.
ABSTRACT
| FULL TEXT
|
